Smith Jamie, Leonard Charles, Carter Dennis L, Tole Shannon
Rocky Mountain Cancer Centers Littleton, Denver, CO, USA.
Rocky Mountain Cancer Centers Aurora, Denver, Co, USA.
Breast Cancer (Dove Med Press). 2021 Aug 29;13:513-517. doi: 10.2147/BCTT.S318197. eCollection 2021.
To report a primary objective clinical outcome of ipsilateral breast cancer recurrence following accelerated partial breast irradiation (APBI) with N (single tumor cells or clusters <2mm) in sentinel lymph nodes. The secondary objective was to observe any incidence of ipsilateral breast failure.
Between March 2004 and April 2016, a total of 747 patients were enrolled in one of two APBI (Accelerated Partial Breast Irradiation) breast protocols (Phase II NCT01185145 and Phase III NCT01185132). Nineteen patients with N disease were treated between February 2005 and December 2015. Patient eligibility included a primary invasive or DCIS tumor size <3 cm, N0(i+) disease, and margin width of >2 mm. All enrolled patients presented in this report had sentinel lymph node examinations. Clinical outcomes of ipsilateral breast, axillary and combined regional (breast or axillary) recurrences were analyzed.
Median follow-up for all patients was 5 years (1-8 years). No patient experienced either ipsilateral breast or axillary recurrence.
There has been scarce information/reporting of the treatment of patients with cytokeratin positive individual tumor cells N with APBI. The authors have presented data which suggest that the successful outcomes of these patients might warrant further study.
报告前哨淋巴结中存在N(单个肿瘤细胞或簇状细胞,直径<2mm)的患者在接受加速部分乳腺照射(APBI)后同侧乳腺癌复发的主要客观临床结局。次要目的是观察同侧乳腺失败的发生率。
2004年3月至2016年4月期间,共有747例患者纳入两项APBI(加速部分乳腺照射)乳腺方案之一(II期NCT01185145和III期NCT01185132)。2005年2月至2015年12月期间,对19例N疾病患者进行了治疗。患者入选标准包括原发性浸润性或导管原位癌肿瘤大小<3cm、N0(i+)疾病以及切缘宽度>2mm。本报告中纳入的所有患者均进行了前哨淋巴结检查。分析了同侧乳腺、腋窝及联合区域(乳腺或腋窝)复发的临床结局。
所有患者的中位随访时间为5年(1 - 8年)。没有患者出现同侧乳腺或腋窝复发。
关于APBI治疗细胞角蛋白阳性单个肿瘤细胞N患者的信息/报道很少。作者提供的数据表明,这些患者的成功结局可能值得进一步研究。